Uncategorized

Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*.

Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development Read More »

Scroll to Top